Overview

Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib

Status:
Terminated

Trial end date:
2010-01-01

Target enrollment:

Participant gender:

Summary

The majority of patients with advanced NSCLC treated with standard platinum based chemotherapy regimens ultimately develop disease progression. Active therapies with improved toxicity profiles are clearly needed in this setting. The primary objective of this trial is to assess the toxicity profile and to determine the effect on progression free survival and time to progression in patients with advanced NSCLC treated with sorafenib in addition to carboplatin and pemetrexed.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University Hospital Muenster

Collaborators:

Bayer
Eli Lilly and Company

Treatments:

Carboplatin
Niacinamide
Pemetrexed
Sorafenib